menu
    • menu
    [{"orgOrder":0,"company":"Autigen","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Autigen Announces Collaboration with Boehringer Ingelheim to Discover and Develop Novel Treatments for Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Discovery","graph3":"Autigen","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autigen \/ Boehringer Ingelheim","highestDevelopmentStatusID":"2","companyTruncated":"Autigen \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Mogrify","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mogrify and Astellas Announce Collaboration to Conduct Research on In Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"AAV-Based Genetic Medicine","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Discovery","graph3":"Mogrify","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mogrify \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Mogrify \/ Astellas Pharma"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Delix Therapeutics Awarded Grant from the U.S. Department of Defense to Advance Neuroplastogen for Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Funding","leadProduct":"Neuroplastogen","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Discovery","graph3":"Delix Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Delix Therapeutics \/ U.S. Department of Defense"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Delix Therapeutics

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Delix Therapeutics

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neuroplastogen

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Discovery

                            Sponsor : U.S. Department of Defense

                            Deal Size : $0.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Delix Therapeutics Awarded Grant from the U.S. Department of Defense to Advance Neuroplastogen for Hearing Los...

                            Details : The financing will support the advancement of a neuroplastogen, a novel, first-in-class, non-toxic, that has been found to repair cochlear synaptopathy that contribute to hidden hearing loss.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 04, 2024

                            Lead Product(s) : Neuroplastogen

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Discovery

                            Sponsor : U.S. Department of Defense

                            Deal Size : $0.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mogrify

                            United Kingdom arrow
                            Luxepack
                            Not Confirmed

                            Mogrify

                            United Kingdom arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV-Based Genetic Medicine

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Discovery

                            Sponsor : Astellas Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Mogrify and Astellas Announce Collaboration to Conduct Research on In Vivo Regenerative Medicine Approaches to...

                            Details : As part of the collaboration, Astellas Gene Therapies, is covering the research cost of the work as well as contributing its expertise in adeno-associated virus based genetic medicine and translational capabilities to complete experiments in pre-clinical...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 05, 2022

                            Lead Product(s) : AAV-Based Genetic Medicine

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Discovery

                            Sponsor : Astellas Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Autigen

                            Country arrow
                            Discovery on Target
                            Not Confirmed

                            Autigen

                            Country arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Discovery

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Autigen Announces Collaboration with Boehringer Ingelheim to Discover and Develop Novel Treatments for Hearing...

                            Details : Collaboration and licensing agreement with Boehringer Ingelheim will advance the discovery, development, and commercialization of novel therapies for sensorineural hearing loss (SHNL), where there are currently no approved pharmacological therapies.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 13, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Discovery

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth